阿柏西普治疗年龄相关性黄斑变性的治疗-延长方案联合退出策略的4年结果
4年随访显示,BCVA在1年时显著提高(从51.9±25.2到63.7±17.7,p<0.0001),4年时与基线无显著差异(58.5±24.3,p=0.22);中央子区域厚度持续显著低于基线;治疗间隔可延长至4年时的11.2±3.5周;29例(35%)患者达到退出标准。结论认为,4年治疗后初始视力增益得以维持,治疗负担合理,即使无初始负荷期,功能结果与大型对照研究相当。
要点
- 无负荷期阿柏西普T&E方案4年可维持初始视力增益,治疗间隔延长至11.2±3.5周。
- 35%患者达到预设退出标准后仅需每3月观察。
- 中央子区域厚度在4年内持续显著低于基线。
核心结论
- 4年阿柏西普T&E治疗(无负荷期)可维持初始视力增益,治疗负担合理,功能结果与大型对照研究相当。
主要发现
- BCVA从基线51.9±25.2 ETDRS字母增至1年63.7±17.7(p<0.0001)、2年61.7±18.5(p<0.0001)、3年62.4±19.5(p<0.0001,n=61),4年58.5±24.3(p=0.22)与基线无显著差异。
- 中央子区域厚度从基线387.5±107.6 μm显著降至1年291.9±65.5 μm(p<0.0001),并持续显著低于基线至4年289.0±59.4 μm(p<0.0001)。
- 治疗间隔1年时可延长至9.3±3.1周,4年时维持11.2±3.5周。
- 29例(35%)患者达到退出标准并转为每3月观察。
关键数值与推荐
- 预设退出标准:达到后治疗期结束,转为每3月观察。
- T&E方案无负荷期。
临床怎么用
- 无负荷期阿柏西普T&E方案可用于nAMD,4年可维持视力增益并延长治疗间隔。
- 达到预设退出标准后可转为每3月观察,减少治疗负担。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To report long-term outcomes on best-corrected visual acuity (BCVA) and treatment intervals with a treat-and-extend (T&E) regimen in patients with neovascular age-related macular degeneration (nAMD). METHODS: This observational study included treatment-naïve patients with nAMD, treated with aflibercept. A specific T&E protocol without a loading phase and predefined exit criteria was administered. After reaching predefined 'exit-criteria', the treatment period was complete, and patients were observed three monthly. RESULTS: Eighty-two patients with a follow-up period of ≥2 years were included. BCVA (mean±SD, ETDRS letters) increased from 51.9±25.2 at baseline to 63.7±17.7 (p<0.0001) at 1 year, 61.7±18.5 (p<0.0001) at 2 years, 62.4±19.5 (p<0.0001, n=61) at 3 years and remained insignificantly higher than baseline at 4 years at 58.5±24.3 (p=0.22). Central subfield thickness (mean±SD, μm) decreased significantly from 387.5±107.6 (p<0.0001) at baseline to 291.9±65.5 (p<0.0001) at 1 year, and remained significantly lower until 4 years at 289.0±59.4 (p<0.0001). Treatment intervals (mean±SD, weeks) could be extended up to 9.3±3.1 weeks at 1 year and remained at 11.2±3.5 weeks at 4 years. Twenty-nine (35%) patients reached exit criteria and continued with three monthly observation only. CONCLUSIONS: After 4 years of treatment, initial vision gains were maintained with a reasonable treatment burden, even without an initial loading phase. Our results on functional outcomes are comparable with large controlled studies.
引用
- Jaggi D, Nagamany T, Ebneter A, et al. Aflibercept for age-related macular degeneration: 4-year outcomes of a 'treat-and-extend' regimen with exit-strategy. Br J Ophthalmol. 2020. PMID: 33127830. doi:10.1136/bjophthalmol-2020-316514
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。